

North Yorkshire & York Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on the 6th December 2023.

Classification of products:

G **Green drug** - Can be initiated and prescribed in all care settings **○**- Second line / alternative green drug.

ASR

Amber Specialist Recommendation drug - Can be recommended by a specialist for initiation in primary care.

ASI

Amber Specialist Initiation drug – Initiated by a specialist and transferred to primary care once the patient stabilised. In some cases there may be a further restriction for use outlined - these will be defined in each case.

ASC

Amber Shared Care drug - These are specialist drugs which must be initiated by the specialist, but with the potential to transfer to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care.

R

Red drug - Drugs that should remain under the total responsibility of the specialist. Usually considered as “hospital only” drugs.

BLACK Not Approved - Drugs that have been considered by the APC or other approved body and are not approved for prescribing within North Yorkshire & York.

GREY Not Reviewed - Drugs that have not been reviewed by the APC yet. This usually means that no application has been received or that an application is in progress. These drugs are not normally considered appropriate for prescribing in North Yorkshire & York.



Product	Decision			Comments/notes
	Approved	Refused	Deferred	
1) Requests deferred from previous meeting				
None				
2) New Requests				
None				
3) New formulations & extensions to use				
None				
5) Products considered by NICE				
TA913: Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
TA914: Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA915: Pegunigalsidase alfa for treating Fabry disease	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA916: Bimekizumab for treating active psoriatic arthritis	✓ R			The formulary will reflect the TAG – ICB is the responsible commissioner.
TA917: Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA918: Bimekizumab for treating axial spondyloarthritis	✓ R			The formulary will reflect the TAG – ICB is the responsible commissioner.
TA919: Rimegepant for treating migraine	✓ G			The formulary will reflect the TAG – ICB is the responsible commissioner.
TA920: Tofacitinib for treating active ankylosing spondylitis	✓ R			The formulary will reflect the TAG – ICB is the responsible commissioner.
TA921: Ruxolitinib for treating polycythaemia vera	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA922: Daridorexant for treating long-term insomnia	✓ G			The formulary will reflect the TAG – ICB is the responsible commissioner. Note: Referred to IPMOC due to financial impact /commissioning implications around CBT.

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
TA923: Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (terminated appraisal)				The formulary will reflect the TAG – NHS England is the responsible commissioner. Received for information.
TA924: Tirzepatide for treating type 2 diabetes	<p>✓ G for 2.5mg and 5mg doses</p> <p>ASR for doses greater than 5mg</p>			The formulary will reflect the TAG – ICB is the responsible commissioner. Note: Referred to IPMOC due to financial impact.
TA925: Mirikizumab for treating moderately to severely active ulcerative colitis	<p>✓ R</p>			The formulary will reflect the TAG – ICB is the responsible commissioner.
TA926: Baricitinib for treating severe alopecia areata	<p>✓ BLACK</p>			The formulary will reflect the TAG – ICB is the responsible commissioner.
TA927: Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments	<p>✓ R</p>			The formulary will reflect the TAG – NHS England is the responsible commissioner.
6) Appeals against earlier decisions by the APC				
Modafinil for fatigue associated with MS	<p>✓ ASC</p>			Decision: approved change from RED to AMBER SC as an option per NICE guidance for fatigue associated with Multiple Sclerosis. This is an unlicensed indication and matches status for us in Parkinsons disease which is also unlicensed and recommended by NICE.
7) Miscellaneous formulary decisions by the APC				
MSK chapter alignment/ review	<p>✓</p>			Decision: approved.
Blood and nutrition chapter alignment/ review	<p>✓</p>			Decision: approved.

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
Anastrozole for primary prevention of breast cancer	✓ ASR			Decision: anastrozole's marketing authorisation now includes a new indication of primary prevention of breast cancer in postmenopausal women at moderate or high risk. The new indication mirrors the pre-existing NICE guideline recommendation in 2017 guidance on familial breast cancer. Locally GPs have been initiated on advice of a specialists usually the clinical genetics service.

The following documents/guidelines were presented to and approved at the December 2023 meeting of the APC:

- NY&Y Vitamin D guidelines – updated with new reference ranges.
- HDFT Fragility Fracture – Secondary prevention Guidelines – update – approved for use across NY&Y.
- HDFT Osteoporosis Guidelines – Full version and Flow chart – update – approved for use across NY&Y.
- NY&Y APC Psoriatic arthritis biologics pathway – update to reflect TA916
- NY&Y APC Biologics Pathway for Axial Spondyloarthritis (Ankylosing Spondylitis) & Non-Radiographic Axial Spondyloarthritis – update to reflect TA918 and TA920
- NY&Y APC Ulcerative colitis biologics pathway - update to reflect TA925
- YSFT Bicalutamide/LHRH analogue letter to GPs

The following guidelines were presented to and recommended for approval to the HNY IPMOC at the December 2023 meeting of the APC:

- NY&Y diabetes pathway updated with tirzepatide

The following shared care guidelines were presented to and approved at the December 2023 meeting of the APC:

- Nil this month.

The following documents/guidelines were presented to the December 2023 meeting of the APC for comment:

- TEWV Clozapine: supporting guidance for primary care
- NY&Y APC Diazoxide shared care